FGF21 and metabolic dysfunction-associated steatohepatitis: The most reported treatment-related side effects were gastrointestinal, especially nausea and diarrhea, and local injection reactions; these were generally mild and did not significantly limit therapy.<h4>Conclusions</h4>FGF21 analogue therapy is associated with significantly greater histological fibrosis improvement in patients with MASH and appears to be well tolerated.